Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous cord blood-derived mononuclear cells
- Development stage
- Unknown
- Lead developer
- Assistance Publique - Hôpitaux de Marseille
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous cord blood-derived mononuclear cells (ACBMNCs) are an investigational cell therapy consisting of a heterogeneous population of mononuclear cells, including hematopoietic stem cells, mesenchymal stem cells, and endothelial progenitor cells, harvested from a newborn's own umbilical cord blood. Developed by the Centre Hospitalier Regional De Marseille (Assistance Publique - Hôpitaux de Marseille) for the treatment of neonatal hypoxic-ischaemic encephalopathy (HIE), this therapy is typically administered intravenously as an adjunct to therapeutic hypothermia. The cells are hypothesized to exert neuroprotective and regenerative effects through paracrine mechanisms, releasing a cocktail of neurotrophic factors and anti-inflammatory cytokines that cross the blood-brain barrier to reduce neuroinflammation, limit apoptosis, and stimulate endogenous neural repair and angiogenesis in the damaged neonatal brain.
- Other names
- autologous umbilical cord blood mononuclear cellsACBMNCautologous cord blood mononuclear cells
Beyond the preview
Go deeper on autologous cord blood-derived mononuclear cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous cord blood-derived mononuclear cells.